Poseida Therapeutics is letting go of 52 employees from its San Diego location, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The layoffs will take effect Oct. 1. It is unclear if the workforce reduction is in connection with the Roche acquisition.
All entries for: Hematology
August 8, 2025
Poseida Therapeutics
Layoffs
San Diego, CA
201-500 employees
Disease Area: Hematology, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
August 8, 2025
Precision BioSciences
Layoffs
Durham, NC
51-200 employees
Delaware-based Precision BioSciences has terminated an undisclosed number of employees in order to extend its cash runway into the second half of 2027.
Disease Area: Chronic Disease, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
August 7, 2025
Bayer
Layoffs
Whippany, NJ
50,001+ employees
Workforce cuts continue at Bayer, with CEO Bill Anderson announcing on the company’s second-quarter earnings call on Aug. 6 that it expects more layoffs to come. These would follow the 2,000 employees it said it was letting go during first-quarter earnings and around 11,000 total since Bayer initiated a sweeping reorganization initiative in July 2023.
Disease Area: Cardiology, Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
July 28, 2025
Fulcrum Therapeutics
Neutral Outlook
Cambridge, MA
51-200 employees
The effect of Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known.
Disease Area: Hematology, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
July 25, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 14, 2025
Karyopharm Therapeutics
Layoffs
Newton, MA
201-500 employees
As it continues exploring options to extend its cash runway, which could include a merger or sale, Karyopharm Therapeutics is cutting about 20% of its workforce, according to a July 11 SEC filing. The Newton, Massachusetts–based commercial-stage pharma did not specify which locations the layoffs affect.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
July 10, 2025
KalVista Pharmaceuticals
Negative Outlook
Cambridge, MA
51-200 employees
While it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of prescription drug products.
Disease Area: Hematology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
July 9, 2025
Jasper Therapeutics
Layoffs
Redwood City, CA
51-200 employees
After “issues” with a batch of its investigational antibody briquilimab “confounded” the readout of Jasper Therapeutics’ Phase Ib/IIa BEACON study in chronic spontaneous urticaria (CSU), the California-based biotech is laying off approximately half of its staff.
Disease Area: Chronic Disease, Hematology, Immune Diseases, Multiple
Drug Type: Biologic
July 8, 2025
CSL Limited
Layoffs
Pasadena, CA
10,001-50,000 employees
The Australian multinational biotech CSL is consolidating its research and development team, according to reporting from Fierce Biotech. The number of employees affected by the consolidation is unclear, though CSL said that more details would be shared at the company’s annual earnings call in August. According to comments made to Fierce, CSL will increasingly rely on external partnerships to bolster its pipeline. The reorganization comes just a month after the company got approval from the FDA for a preventive for attacks in patients with hereditary angioedema.
Disease Area: Hematology, Infectious Diseases, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
July 2, 2025
Oncternal Therapeutics
Company Closure
San Diego, CA
1-50 employees
San Diego-based Oncternal Therapeutics is closing shop. To oversee the wind-down process, the company will retain only one employee: Craig Jalbert, a principal of the accounting firm Verdolino & Lowey, P.C. He will act as Oncternal’s president, CEO, treasurer, secretary and sole member of its board of directors. All remaining executives, directors and employees of Oncternal have resigned, though it’s not immediately clear how many people will be directly affected by the company’s closure. In September 2024, the biotech downsized by 37%, corresponding to about 10 employees, including its Chief Medical Officer Salim Yazji.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule